10:25:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-27 Ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-05-29 Kvartalsrapport 2024-Q1
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2023-03-13 17:10:51
With reference to the stock exchange announcements from SoftOx Solutions AS
("SoftOx" or the "Company") on February 15, 2023, on the challenging liquidity
situation and on March 8, 2023, the webcast presentation. The Company provides
an update on the financing process and the company status.



Financing

SoftOx is working diligently on securing both its short-term and long-term
financing. The company is in close dialogue with both existing stakeholders and
interested outside investors. SoftOx is currently in discussions with a select
number of investors, and the company is evaluating different potential models.
The aim is to secure approx. NOK 40 million, to secure the company runway for 6
months. Payment from the European Defence Fund is expected but not included in
the Company's budgets going forward.



If the Company decides to propose a solution with a basis from new investors, it
is the intention that the existing shareholders will be given ample
opportunities to also participate. SoftOx would like to underline that there is
uncertainty as to whether a solution with outside investors may materialise at
this point.



Company status

SoftOx has recently reached several important milestones in its product
development and believes that the underlying values are material. All completed
studies have shown excellent clinical results and confirmed safety and
tolerability with a broad spectrum of antiviral and antimicrobial effects. In
the treatment for leg ulcers, it was observed over 99% reduction in bacterial
burden in the wound together with observed dose dependent reduction in wound
size with 24% reduction in wound size in the group which received treatment one
time per day in 5 days and 36% reduction in wound size in the group which
received treatment with SoftOx two times per day in 5 days. External health
economic models from EXCITE International estimate the health economic saving by
faster wound healing and avoiding infections in leg ulcers to be up to USD 6,404
per patient, which would give up to USD 14 billion in reduced health care cost
in the US alone. For the infectious disease (SIS) project, the Company observed
infection prevention ability in an influenza-like mouse model together with
tolerability and safety in phase 1.



As material financing discussions are ongoing, the company has decided to
postpone its announced extended presentation scheduled for March 14, 2023.
However, attached to this release is an extended presentation that describes the
technology development, results and progress in detail.



SoftOx will revert with further updates in due course.


For further information, please contact:
Geir Almås, Executive Chairman of SoftOx Solutions AS

Christian Harstad, Interim CEO of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance. For
more information on SoftOx, visit www.soft-ox.com